gadodiamide (Omniscan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Gadodiamide is a nonionic, low-osmolar gadolinium-based contrast agent for diagnostic contrast-enhanced magnetic resonance imaging (MRI).   NCATS

Chemistry

  • SMILES: [Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O
  • InChIKey: HZHFFEYYPYZMNU-UHFFFAOYSA-K
  • Mol. Mass: 573.66
  • ALogP: Missing data
  • ChEMBL Molecule:
    gadodiamide  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$7.5560 - $155.7940
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

amersham brand of gadodiamide | gadodiamide | gadodiamide anhydrous | gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate | gd-dtpa bis-(methylamide) | gd-dtpa-bma | gddtpa-bma | nycomed brand of gadodiamide | omniscan | omniscan unique softpack | s-041 | sanofi winthrop brand of gadodiamide

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Diagnostic Imaging (approved 1993)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Aortic Stenosis, Subvalvular (Phase 3)

Arterial Occlusive Diseases (Phase 3)

Cognition (Phase 4)

Contrast Media (Phase 4)

Motor Activity (Phase 4)

Nephrogenic Fibrosing Dermopathy (Phase 4)

Renal Artery Obstruction (Phase 3)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue